Aspirin as adjunctive treatment for giant cell arteritis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Mollan, Susan P ^a   Marrone, Michael ^b   Burdon, Mike A ^a   Levin, Leonard A ^c,d   Denniston, Alastair K ^a,e  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; STOMACH HEMORRHAGE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TINNITUS; TREATMENT OUTCOME;

EID: 84991241624     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010453     Document Type: Article

References (44)

1. Ainsworth RW, Gresham GA, Balmforth GV. Pathological changes in temporal arteries removed from unselected cadavers. Journal of Clinical Pathology 1961;14:115-9.
2. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: Results in 55 cases in which the lesion was proved at biopsy. Journal of the American Medical Association 1957;163:821.
3. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmune Reviews 2012;11(6-7):A544-54.
4. Chan CC, Paine M, O'day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. Journal of Neuro-Ophthalmology 2005;25(1):14-7.
5. Crow RW, Katz BJ, Warner JE, Alder SC, Zhang K, Schulman S, et al.Giant cell arteritis and mortality. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2009;64(3):365-9.
6. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al.BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010;49(8):1594-7.
7. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Annals of the Rheumatic Diseases 1986;45(2):136-8.
8. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
9. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Annals of Internal Medicine 1995;122(7):502-7.
10. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
11. Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al.Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 2004;83(6):342-7.
12. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. American Journal of Ophthalmology 1998;125(4):521-6.
13. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003;217(4):239-59.
14. Hellmann DB. Low dose aspirin in the treatment of giant cell arteritis. Arthritis and Rheumatism 2004;50(4):1026-7.
15. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Hill CL, Cole A, Lester S, Whittle SL. Steroid sparing drug treatments for giant cell arteritis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005323.pub2].
17. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al.A multicenter, randomized, double blind placebo controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism 2002;46(5):1309-18.
18. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al.Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Annals of Internal Medicine 2007;146(9):621-30.
19. Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM, Rehman MU. Aspirin and immune system. International Immunopharmacology 2012;12(1):10-20.
20. Kim N, Trobe JD, Flint A, Keoleian G. Late ipsilateral recurrence of ischemic optic neuropathy in giant cell arteritis. Journal of Neuro-Ophthalmology 2003;23(2):122-6.
21. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al.Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism 1998;41(5):778-99.
22. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis and Rheumatism 2006;54(10):3306-9.
23. Ly KH, Régent A, Tamby MC, Mouthon L. Pathogenesis of giant cell arteritis: More than just an inflammatory condition?. Autoimmune Reviews 2010;9(10):635-45.
24. Machado EB, Michet CJ, Ballard DJ, Hunder GG, Beard CM, Chu CP, et al.Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-85. Arthritis and Rheumatism 1988;31(6):745-9.
25. Mahr A, Saba M, Kambouchner M, Polivka M, Baudrimont M, Brochériou I, et al.Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?. Annals of the Rheumatic Diseases 2006;65(6):826-8.
26. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al.Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis and Rheumatism 2007;56(8):2789-97.
27. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al.Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis and Rheumatism 2006;54(10):3310-8.
28. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis and Rheumatism 2004;50(4):1332-7.
29. Nesher G, Berkun Y, Mates M, Baras M, Nesher R, Rubinow A, et al.Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004;83(2):114-22.
30. Niederkohr RD, Levin LA. Management of the patient with suspected temporal arteritis: a decision-analytic approach. Ophthalmology 2005;112(5):744-56.
31. Niederkohr RD, Levin LA. A Bayesian analysis of the true sensitivity of a temporal artery biopsy. Investigative Ophthalmology and Visual Science 2007;48(2):675-80.
32. Nordborg E, Bengtsson BA. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 1989;299(6698):549-50.
33. Ostberg G. An arteritis with special reference to polymyalgia arteritica. Acta Pathologica et Microbiologica Scandinavica 1973;Suppl 237:1-59.
34. Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology 1999;38(12):1208-12.
35. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
36. Rüegg S, Engelter S, Jeanneret C, Hetzel A, Probst A, Steck AJ, et al.Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature. Medicine 2003;82(1):1-12.
37. Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al.Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis and Rheumatism 2005;53(2):293-7.
38. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372(9634):234-45.
39. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Smetana GW, Shmerling RH. Does this patient have temporal arteritis?. JAMA 2002;287(1):92-101.
41. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Archives of Internal Medicine 2002;162(19):2197-202.
42. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis and Rheumatism 2002;46(2):457-66.
43. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmune Reviews 2004;3(1):46-53.
44. Weyand CM, Younge BR, Goronzy JJ. IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Current Opinion in Rheumatology 2011;23(1):43-9.